CAMBRIDGE, Mass., Jan. 6 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will be
participating at the 22nd Annual JPMorgan Healthcare Conference being held in
San Francisco, California, January 12-15, 2004. TKT's presentation will be at
4:30 p.m. Pacific Time on Tuesday, January 13, 2004. During the presentation,
Michael J. Astrue, President and Chief Executive Officer of TKT expects to
provide an update on the company's three lead programs and other business
activities. The live audio webcast and replay of this presentation may be
accessed on the Internet at http://www.tktx.com under the Investor Information
section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company committed to
developing treatments for rare diseases caused by protein deficiencies with a
core focus on lysosomal storage diseases. The company markets one product,
Replagal(TM), an enzyme replacement therapy for Fabry disease in Europe and
other countries and is developing treatments for Hunter syndrome and Gaucher
disease. TKT's research pipeline is focused on rare diseases where a
significant unmet medical need exists. TKT was founded in 1988 and is
headquartered in Cambridge, Massachusetts, with additional operations in
Europe and Latin America. Additional information about TKT is available on
the company's website at http://www.tktx.com.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
Contact:
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Specialist of Transkaryotic Therapies, Inc., +1-617-349-0205
|
